Key result
In pediatric Hodgkin lymphoma survivors treated with ABVD, no secondary malignancies occurred at 10.3 years, but subclinical hypothyroidism and abnormal spirometry were common.
Why the study?
ABVD is not standard in children due to concerns regarding late effects, and no studies had evaluated its long-term toxicities in pediatric patients.
Does ABVD treatment cause late cardiac, pulmonary, and thyroid toxicities in pediatric Hodgkin lymphoma survivors?
Cohort (n=154)
No
Does ABVD treatment cause late cardiac, pulmonary, and thyroid toxicities in pediatric Hodgkin lymphoma survivors?
ABVD appears safe regarding symptomatic late effects in pediatric Hodgkin lymphoma survivors at 10 years, though subclinical pulmonary and thyroid abnormalities are common, especially with neck radiation.
Answers are grounded in this paper and cite their sources.
Warrants surveillance for subclinical thyroid and pulmonary issues after pediatric ABVD; leaves open longer-term symptomatic and malignancy risks.
PURPOSE: ABVD (doxorubicin, bleomycin,vinblastine, and dacarbazine) is not a standard regimen in children due to concerns regarding late effects. However, no studies have evaluated long-term toxicities of ABVD in children. METHODS: Total 154 pediatric Hodgkin lymphoma (HL) survivors uniformly treated with ABVD were clinically followed up as per institutional protocol. All participants were evaluated for cardiac, pulmonary, and thyroid function abnormalities by multigated acquisition scan (MUGA) scan, spirometry with diffusion capacity of lung for the uptake of carbon monoxide (DLCO), and thyroid profile test, respectively, at a single time point. Predictors of toxicity were also analyzed. RESULTS: The median duration of follow-up of the cohort was 10.3 years (6.04-16.8). No secondary malignant neoplasm (SMN) or symptomatic cardiac/pulmonary toxicities were detected. Nine patients (5.9%) had left ventricular ejection fraction (LVEF) <55%. Subclinical and overt hypothyroidism were observed in 78 (50.6%) and 16 (10.4%) survivors, respectively. Abnormal spirometry and reduced DLCO was observed in 43.2% and 42.0% survivors, respectively. Receiving neck radiation was significantly associated with thyroid dysfunction (odds ratio [OR] 16.04, p < .001); age ≥10 years predicted reduced DLCO (OR 4.12, p = .001). Sixty-three and 33 patients had one and two late adverse effects, respectively; receiving neck radiation predicted development of multiple late effects (proportional OR 4.72, p < 0.001). Cumulative dose of chemotherapy did not predict toxicity. CONCLUSIONS: Overall, ABVD appears safe in children at a relatively short follow-up. Long-term safety data are required before it can be adopted for treating pediatric HL patients. Children receiving neck radiation require close follow-up.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2021) conducted a cohort in pediatric Hodgkin lymphoma (n=154). ABVD with or without radiotherapy was evaluated on cardiac, pulmonary, and thyroid function abnormalities. In pediatric Hodgkin lymphoma survivors treated with ABVD, no secondary malignancies occurred at 10.3 years, but subclinical hypothyroidism and abnormal spirometry were common.
Synapse has enriched 10 related papers. Consider them for comparative context: